-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Bionano Genomics Announces Launch Of CLIA-Certified Bionano Laboratories, And Expands Its Clinical Testing Menu With Launch Of First OGM-Based LDT For FSHD
Bionano Genomics Announces Launch Of CLIA-Certified Bionano Laboratories, And Expands Its Clinical Testing Menu With Launch Of First OGM-Based LDT For FSHD
Bionano Genomics, Inc. (NASDAQ:BNGO) today announced the launch of Bionano Laboratories, a new organization that combines Bionano's optical genome mapping (OGM) data services with the clinical testing services previously offered by Lineagen, and the launch of Bionano Laboratories' first OGM-based laboratory developed test (LDT). Bionano Laboratories recently received CLIA-certification for its lab in San Diego. This certification will enable Bionano Laboratories to offer services to customers seeking to implement OGM into their diagnostic routines and for research applications with hospitals, pharmaceutical companies, and other parties that may desire a more robust regulatory structure for their projects.
A key strategic objective of Bionano Laboratories' CLIA lab is to develop a menu of LDTs based on OGM. The first OGM-based LDT developed by Bionano Laboratories is a test for facioscapulohumeral muscular dystrophy (FSHD), which is the second leading cause of muscular dystrophy and an important marker in the evaluation of muscular disorders.
"We are excited to launch Bionano Laboratories, which will enable the ability to scale OGM LDT and research services to meet increasing market testing demands. We believe our CLIA-certified lab will help streamline the diagnostic odyssey for clinicians and their patients, as it will have the potential to detect many different types of genomic variants in a single diagnostic environment. This launch is an important milestone for Bionano, and something we have been working towards since our acquisition of Lineagen," commented Dr. Alka Chaubey, chief medical officer of Bionano Genomics.
Erik Holmlin, PhD, president and chief executive officer of Bionano Genomics added, "We want to congratulate Alka along with her outstanding team for all the work they've done. The development of LDTs will allow Bionano Laboratories to introduce OGM-based assays to interested physicians and to seek reimbursement from insurance companies for these testing services. We believe our ability to offer CLIA-certified services will enable us to execute our growth strategy and to fulfill our vision of changing the way the world sees the genome."
More details on Bionano Laboratories is available at:
Bionano Genomics, Inc. (NASDAQ:BNGO) today announced the launch of Bionano Laboratories, a new organization that combines Bionano's optical genome mapping (OGM) data services with the clinical testing services previously offered by Lineagen, and the launch of Bionano Laboratories' first OGM-based laboratory developed test (LDT). Bionano Laboratories recently received CLIA-certification for its lab in San Diego. This certification will enable Bionano Laboratories to offer services to customers seeking to implement OGM into their diagnostic routines and for research applications with hospitals, pharmaceutical companies, and other parties that may desire a more robust regulatory structure for their projects.
Bionano Genomics, Inc.(納斯達克股票代碼:BNGO)今天宣佈成立Bionano Laboratories,這是一家將Bionano的光學基因組映射(OGM)數據服務與Lineagen先前提供的臨床測試服務相結合的新組織,並啓動了Bionano Laboratories的首個基於OGM的實驗室開發的測試(LDT)。Bionano 實驗室最近獲得了其位於聖地亞哥的實驗室的 CLIA 認證。該認證將使Bionano Laboratories能夠爲尋求在其診斷程序中實施OGM的客戶提供服務,併爲醫院、製藥公司和其他可能希望爲其項目建立更強有力的監管結構的各方提供研究應用。
A key strategic objective of Bionano Laboratories' CLIA lab is to develop a menu of LDTs based on OGM. The first OGM-based LDT developed by Bionano Laboratories is a test for facioscapulohumeral muscular dystrophy (FSHD), which is the second leading cause of muscular dystrophy and an important marker in the evaluation of muscular disorders.
Bionano Laboratories的CLIA實驗室的一個關鍵戰略目標是開發基於OGM的LDT菜單。Bionano Laboratories開發的第一個基於OGM的LDT是面肩部肌營養不良症(FSHD)的測試,這是肌肉萎縮症的第二大病因,也是評估肌肉疾病的重要標誌。
"We are excited to launch Bionano Laboratories, which will enable the ability to scale OGM LDT and research services to meet increasing market testing demands. We believe our CLIA-certified lab will help streamline the diagnostic odyssey for clinicians and their patients, as it will have the potential to detect many different types of genomic variants in a single diagnostic environment. This launch is an important milestone for Bionano, and something we have been working towards since our acquisition of Lineagen," commented Dr. Alka Chaubey, chief medical officer of Bionano Genomics.
“我們很高興推出Bionano Laboratories,這將使我們能夠擴展OGM LDT和研究服務,以滿足不斷增長的市場測試需求。我們相信,我們的CLIA認證實驗室將有助於簡化臨床醫生及其患者的診斷之旅,因爲它有可能在單一診斷環境中檢測出許多不同類型的基因組變異。此次發佈對Bionano來說是一個重要的里程碑,也是自收購Lineagen以來我們一直在努力實現的目標。” Bionano Genomics首席醫學官Alka Chaubey博士評論說。
Erik Holmlin, PhD, president and chief executive officer of Bionano Genomics added, "We want to congratulate Alka along with her outstanding team for all the work they've done. The development of LDTs will allow Bionano Laboratories to introduce OGM-based assays to interested physicians and to seek reimbursement from insurance companies for these testing services. We believe our ability to offer CLIA-certified services will enable us to execute our growth strategy and to fulfill our vision of changing the way the world sees the genome."
Bionano Genomics總裁兼首席執行官埃裏克·霍姆林博士補充說:“我們要祝賀Alka及其出色的團隊所做的所有工作。LDT的開發將使Bionano Laboratories能夠向感興趣的醫生介紹基於OGM的檢測,併爲這些測試服務尋求保險公司的報銷。我們相信,我們提供CLIA認證服務的能力將使我們能夠執行增長戰略,實現改變世界看待基因組的方式的願景。”
More details on Bionano Laboratories is available at:
有關 Bionano 實驗室的更多詳細信息,請訪問:
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧